Manufacturer of Controlled Substances, Notice of Registration; Morton Grove Pharmaceuticals, 5503 [2013-01592]
Download as PDF
<![CDATA[
5503
Federal Register / Vol. 78, No. 17 / Friday, January 25, 2013 / Notices
Drug
Schedule
Dextropropoxyphene, bulk (non-dosage forms) (9273) ..............................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
Levo-alphacetylmethadol (9648) .................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Noroxymorphone (9668) ..............................................................................................................................................................................
Racemethorphan (9732) ..............................................................................................................................................................................
Alfentanil (9737) ..........................................................................................................................................................................................
Remifentanil (9739) .....................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Carfentanil (9743) ........................................................................................................................................................................................
Tapentadol (9780) .......................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cerilliant Corporation to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Cerilliant Corporation to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 15, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
manufacturer of Gamma Hydroxybutyric
Acid (2010), a basic class of controlled
substance listed in schedule I.
The company plans to manufacture
the listed controlled substance for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Morton Grove Pharmaceuticals to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Morton Grove
Pharmaceuticals to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic class of
controlled substance listed.
Dated: January 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–01533 Filed 1–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[FR Doc. 2013–01592 Filed 1–24–13; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
mstockstill on DSK4VPTVN1PROD with
Manufacturer of Controlled
Substances, Notice of Registration;
Morton Grove Pharmaceuticals
By Notice dated September 25, 2012,
and published in the Federal Register
on October 2, 2012, 77 FR 60144,
Morton Grove Pharmaceuticals, 6451
Main Street, Morton Grove, Illinois
60053–2633, made application by letter
to the Drug Enforcement Administration
(DEA) to be registered as a bulk
VerDate Mar<15>2010
18:39 Jan 24, 2013
Jkt 229001
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Statement
of Expenditures and Financial
Adjustment of Federal Funds for
Unemployment Compensation for
Federal Employees and ExServicemembers
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the Employment
and Training Administration (ETA)
sponsored information collection
request (ICR) titled, ‘‘Statement of
Expenditures and Financial Adjustment
of Federal Funds for Unemployment
Compensation for Federal Employees
and Ex-Servicemembers,’’ (Reporting
Form ETA–191) to the Office of
Management and Budget (OMB) for
review and approval for continued use
in accordance with the Paperwork
Reduction Act (PRA) of 1995 (44 U.S.C.
3501 et seq.).
DATES: Submit comments on or before
February 25, 2013.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained from the RegInfo.gov
Web site, https://www.reginfo.gov/
public/do/PRAMain, on the day
following publication of this notice or
by contacting Michel Smyth by
telephone at 202–693–4129 (this is not
a toll-free number) or sending an email
to DOL_PRA_PUBLIC@dol.gov.
Submit comments about this request
to the Office of Information and
Regulatory Affairs, Attn: OMB Desk
Officer for DOL–ETA, Office of
Management and Budget, Room 10235,
725 17th Street NW., Washington, DC
20503, Fax: 202–395–6881 (this is not a
SUMMARY:
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 78, Number 17 (Friday, January 25, 2013)]
[Notices]
[Page 5503]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01592]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances, Notice of Registration;
Morton Grove Pharmaceuticals
By Notice dated September 25, 2012, and published in the Federal
Register on October 2, 2012, 77 FR 60144, Morton Grove Pharmaceuticals,
6451 Main Street, Morton Grove, Illinois 60053-2633, made application
by letter to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic
class of controlled substance listed in schedule I.
The company plans to manufacture the listed controlled substance
for distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a), and determined that the registration
of Morton Grove Pharmaceuticals to manufacture the listed basic class
of controlled substance is consistent with the public interest at this
time. DEA has investigated Morton Grove Pharmaceuticals to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems; verification of the company's compliance
with state and local laws; and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic class of controlled substance listed.
Dated: January 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-01592 Filed 1-24-13; 8:45 am]
BILLING CODE 4410-09-P
